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ABSTRACT

As the baby boomer generation continues to age, the diagnosis of osteoporosis and its side
effects will continue to increase. Denosumab and bisphosphonates (BPs) are some of the most
common medication classes used to treat osteopenia and osteoporosis, but it is believed that both
medications have the possible side effect of medication-related osteonecrosis of the jaw
(MRONJ). The purpose of this paper is to uncover if MRONJ is a side effect of osteoporosis
treatment and which medication carries the highest incidence rate. Through a review of several
electronic databases and several peer reviewed research articles, a wide range of reported
incidence rates of MRONJ for both medications were uncovered, along with many compounding
possible risk factors. There is the wide range of reported incidence rates among different studies.
Through the research, it is found that denosumab carries a slightly higher risk of MRONJ versus
bisphosphonates, but the difference was found to be statistically insignificant. Founded risk
factors include increasing age, gender, recent dental procedures, history of oral disease, and
corticosteroid use. My research is impactful in the fact that as providers, we can be better
informed about the differences between denosumab and bisphosphonates and the possible risk
factors of MRONJ. We can use the information, along with possible other risk factors and our
patient’s history, to make joint decisions about what osteoporosis medication is right for our
patients.
Keywords: osteonecrosis, jaw, medication-related, bisphosphonates side effects,
denosumab side effects, abnormal fracture, osteoporosis
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INTRODUCTION

The world’s population is ageing: virtually every country in the world is experiencing
growth in the number and proportion of older persons in their population, and the United States
is no exception. Two factors—longer life spans and aging baby boomers—will combine to
double the population of Americans aged 65 years and older during the next 25 years to about 72
million (CDC, 2013). By 2030, older adults will account for roughly 20% of the U.S. population,
up from almost 14 percent in 2012 (CDC, 2013). This will have a significant impact on health
care the age-related medical issues of aging; a loss of bone mineralization and bone mass in the
forms of osteopenia and osteoporosis being a major issue. By definition from the World Health
Organization (WHO), osteopenia is defined as a T-score of -1 to -2.5 measured by bone
densitometry, while a score of less than -2.5 is diagnosed as osteoporosis. In other words,
osteopenia is caused by a loss of bone density, with osteoporosis being a more severe condition.
The United States Preventive Services Task Force (USPSTF) has a B grade recommendation for
screening of osteopenia and osteoporosis via bone densitometry scan in women 65 years and
older and in younger women whose fracture risk is equal to or greater than that of a 65-year old
woman who have no additional risk factors (USPSTF, 2016). A grade B recommendation
equates that the USPSTF recommends the service and that there is a high certainty that the net
benefit is moderate compared to the risks. There is insufficient evidence to assess the balance of
benefits and harms of screening in men (USPSTF, 2016).
Postmenopausal women are at greatest risk of developing osteoporosis due to accelerated
loss in bone mass associated with the first several years of menopause (International
Osteoporosis Foundation, 2017). 200 million women are affected worldwide, with incidence
rates increasing with age (International Osteoporosis Foundation, 2017). According to the
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International Osteoporosis foundation, worldwide osteoporosis causes more than 8.9 million
fractures annually, resulting in an osteoporotic fracture every three seconds (International
Osteoporosis Foundation, 2017). 24.5% of women and 5.1% of men aged 65 years and over with
osteoporosis will experience a fracture of the femur or lumbar spine, according to the CDC
(CDC, 2013). As the average life expectancy continues to increase, the frequency of developing
fractures and costs associated with the disease are expected to more than double by 2026
(International Osteoporosis Foundation, 2017).
In addition to the personal burden and impact on quality of life, the costs associated with
fracture treatment and rehabilitation are enormous. In Europe, the disability due to osteoporosis
is greater than the causes by cancers, with the exception of lung cancer, and the lifetime cost is
comparable or greater than many chronic diseases, such as asthma or high blood pressure
(International Osteoporosis Foundation, 2017). A study from 2002 estimated national health care
expenditures attributed to osteoporosis fractures for people aged 45 years and older to be about
$12 billion annually, with approximately 75% of the costs attributed for direct medical care
associated with inpatient services, nursing home care, and outpatient services (Desai, Duncan,
Sloan, 2003).
There are many different pharmacologic and non-pharmacologic treatment approaches to
osteoporosis. Denosumab and BPs are two of the most common pharmacologic treatments
prescribed for osteoporosis. However, both are not without their various side effects. Both
medications have a possible side effect of osteonecrosis of the jaw, but in family practice, this is
believed to be very rare. Through a literature review, I seek to answer the question of which
medication class has the lowest incidence rate of osteonecrosis of the jaw as a side effect of the
treatment for osteoporosis.
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Statement of the Problem
There are many different approaches to treating osteoporosis. Denosumab and
bisphosphonates are two of the most common pharmacologic treatments prescribed. However,
both are not without their various side effects. Both medications are believed to have the possible
side effect of osteonecrosis of the jaw, but this is believed to be very rare.
Statement of the Research Questions
Is the incidence rate of MRONJ greater in those patients treated with denosumab or
bisphosphonates? Are there any precipitating factors or conditions that increases incidence rates
of MRONJ with treatment of denosumab or bisphosphonates?

REVIEW OF LITERATURE
A comprehensive search was performed using several electronic databases, including
CINAHL, PubMed, Clinical Key, and DynaMed Plus. Specific search keywords included:
osteonecrosis, jaw, medication-related, bisphosphonates side effects, denosumab side effects,
abnormal fracture, osteoporosis. A review of the literature yielded several high-quality reviews
of randomized controlled trials, prospective cohort studies, and case control studies with clinical
ascertainment of MRONJ. Studies were limited to those with the highest levels of evidence,
those published after 2008, and to those with the highest level of evidence. Some articles were
used to provide background information on pathophysiology of osteonecrosis of the jaw (ONJ).
Several studies were excluded as they compared MRONJ in patients given the medications
solely for cancer treatment, not for treatment of osteoporosis.
The drawback to many of the studies is the inconsistencies of the different study
conditions, including length of treatment, age of patients, and varied sample sizes. Many studies
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reported incidence rates, but did not state any other conditions of the studies. As the authors
reported in the Journal of Oral and Maxillofacial Surgeons in 2014, the studies compared had
sample sizes varying from 233 participants to 90,000 (see figure three).
Background information of bone physiology:
Osteopenia and osteoporosis are gradual processes, with many compounding contributing
factors. The basic pathophysiology of bone loss is due to normal age-related changes in bone
remodeling, as well as extrinsic and intrinsic factors that exaggerate this process. After age 30 to
45, the resorption and formation processes become imbalanced, and bone resorption exceeds
formation (Lindsay & Cosman, 2014). This imbalance may begin at different ages and varies at
different skeletal sites. Excessive bone loss can be due to an increase in osteoclastic activity
and/or a decrease in osteoblastic activity. Increased number of bone remodeling site produces a
reduction in bone tissue, and can result in permanent loss of tissue and disordered skeletal
architecture. In cortical bone, increased remodeling creates more porous bone with decreased
overall strength.
The imbalance between bone resorption and remodeling becomes more exaggerated in
women after menopause. Estrogen deficiency is believed to cause bone loss by activation of new
bone remodeling sites that exaggerates the imbalance between bone formation and resorption
The belief of the importance of estrogen for bone formation and strength is consistent with the
most osteoporosis cases occurring in post-menopausal women, when a naturally steady decline
in the amount of estrogen occurs (Lindsay & Cosman, 2014).
Many factors can increase the process of bone loss. Inadequate calcium during growth
may impair peak bone mass. During adulthood, insufficient calcium intake contributes to relative
secondary hyperparathyroidism and increases the rate of bone resorption to maintain normal
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serum calcium levels. Vitamin D deficiency can also lead to compensatory secondary
hyperparathyroidism and is an important risk factor for osteoporosis, leading to increased bone
resorption inactivity can also result in significant bone loss. A large number of medications are
potentially detrimental to bone strength, with the most common cause being glucocorticoids. The
use of cigarettes over a significant period can also affect bone moss, both directly by its toxic
effects or indirectly by modifying estrogen metabolism (Lindsay & Cosman, 2014).
MRONJ definition:
In 2003, Marx reported the first cases of what now become known as MRONJ (Coropiuc
et al., 2017). Initially, osteonecrosis was reported only after treatment with bisphosphonates and
was referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ). As other
antiresorptive classes, like denosumab, seemed to lead to the same outcome, the term was soon
altered to antiresorptive-related osteonecrosis of the jaw (ARONJ). Since 2014, the American
Association of Oral and Maxillofacial Surgeons (AAOMS) has recommended the use of the term
“medication-related osteonecrosis of the jaw” (MRONJ). This change is to better accommodate
the growing number of cases of osteonecrosis that are associated with other anti-resorptives in
patients who have not used bisphosphonates previously (Coropiuc et al., 2017).
To distinguish MRONJ from other delayed healing conditions and address evolving
clinical observations and concerns about under-reporting of disease, the working definition of
MRONJ has been modified from the 2009 AAOMS position paper (Ruggiero et al., 2014).
Patients are considered to have MRONJ if all the following characteristics are present:
•

Current or previous treatment with antiresorptive or antiangiogenic agents

•

Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the
maxillofacial region that has persisted for longer than 8 weeks
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No history of radiation therapy to the jaws or obvious metastatic disease to the jaws
ONJ has three intensity stages, determined by the patient’s symptoms and defects of the
oral mucosa with bone exposure. But different agencies have different concepts on each
stage criteria (see table one below)

Table 1: Different ONJ staging systems

Note. Adapted from “Medication-related osteonecrosis of the jaw in oncological patients with
skeletal metastases,” by R. Coropciuc, K. Grisar, T. Aerden, M. Schol, J. Schoenaers, and C.
Politis, 2017, British Journal of Oral and Maxillofacial Surgery, 55, p. 787-792. Copyright
British Association of Oral and Maxillofacial Surgeons
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Mode of action of denosumab and bisphosphonates:
There are two main pharmacological approaches to osteoporosis: anabolic therapy, which
stimulates new bone formation; and anticatabolic or antiresorptive therapy, which decreases bone
resorption and/or inhibits bone turnover. Of the antiresorptive therapies, BPs are the most widely
used for patients with osteoporosis. All BPs directly suppress resorption by inhibiting osteoclast
attachment and enhancing programmed cell death. Those osteoclasts that do survive have
reduced resorptive activity. The three most common first-line BPs are alendronate, risedronate,
and zoledronic acid. All treatments are nitrogen-containing, which target a specific metabolic
enzyme, farnesyl pyrophosphate synthase (FPPS), which prevents the normal development
proteins required for osteoclast function and survival (Hanley, Adachi, Bell & Brown, 2012).
Denosumab is one of the newest antiresorptive agents. It was the first FDA-approved
biologic for the treatment of osteoporosis in both men and women (De Paula, Black, & Rosen
2016). Denosumab is a fully human monoclonal antibody to an osteoclast-differentiating
receptor activator of nuclear factor-kappa B (RANK). The antibody binds directly to RANK
ligand, which results in activation of hematopoietic cells of the osteoclast lineage, beginning the
process of bone resorption (De Paula et al., 2016). By blocking this activation, denosumab
inhibits osteoclast recruitment and maturation, slowing bone resorption. (Hanley et al., 2012). As
a result, the medication increases bone mass density, and hence reduces the risk of fracture.
Unlike BPs, denosumab does not persist in the skeleton long-term and needs to be administered
once every six months to maintain efficacy. In fact, discontinuation of denosumab can lead to a
rebound increase in bone resorption (De Paula et al., 2016).
One major difference between the two medication classes is the length of time the
medication is taken. It is suggested that patients taking BPs for approximately five years
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discontinue therapy as there appears to be residual bone density and fracture benefit, and there is
no evidence that continuing therapy further increases bone density (Rosen, 2017). Denosumab on
the other hand can be considered a life-sentence, because once a patient begins treatment, the
patient’s bone density can rapidly decrease once a dose is missed, so the medication is
recommended to be continued chronically.
Other differences between the two medications include indication and cost. The
indication for denosumab is having a diagnosis of osteoporosis at any location in the body via
bone density scan. The medication is not to be taken for osteopenia without an osteoporosis
diagnosis of at least one location in the body. BPs can be taken with for a diagnosis of either
osteopenia or osteoporosis. Cost could also affect which medication is available to patients.
Although both medications are usually well covered by insurance, one dose of a common BP
averages about $200, while one dose of denosumab can cost up to $1,100 (Desai et al., 2003).
Incidence rate of ONJ with denosumab and bisphosphonates:
My research had uncovered a wide variety of reported incidence rates of MRONJ.
In the osteoporosis patient population, the incidence of MRONJ is estimated to be about
0.001-0.1%, marginally higher than the incidence rate in the general population at less than
0.001% (Svejda et al., 2016).
In patients with osteoporosis exposed to placebo agents, the risk of ONJ rages from 0% to
0.2% (Dodson, 2014). For those patients taking zoledronate, a BP, the risk for MRONJ is 0.02%
and approximates to the risk for MRONJ in patients exposed to placebo. For patients treated with
denosumab, the risk for MRONJ ranges from 0.04% to 0.2% (Dodson, 2014). In 2008, 5.1
million patients older than 55 years received a prescription for BPs. A recent federal study
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estimates that the prevalence of BP exposure was seven for every 100 persons in the United
States who received a prescription for a BP in the outpatient setting (Dodson, 2014).
In a cross-sectional survey study of more than 13,000 patients, the prevalence of MRONJ
in those receiving long-term oral BP therapy was reported at 0.1%. Felsenberg and Hoffmeister
(2014) reported a prevalence of MRONJ among patients treated with BPs for osteoporosis of
0.0004%, which equates to less than one case per 100,000 patients exposed, based on reports to
the German Central Registry of Necrosis of the Jaw. In a more recent report, Malden and Lopes
(2012) derived an incidence report that 0.004% of patients exposed to a BP from 11 cases of
MRONJ reported in a population of 90,000 people living in southeast Scotland. The advantage of
these studies is the high population studied. But the other conditions of the studies, including
demographics of the patients and time frame of the study is unknown. Based on a case-control
study, the risk of MRONJ was 13.1 times greater among patients exposed to oral BPs than in
patients without exposure (Dodson, 2014).
According to DynaMed Plus, the estimated incidence of MRONJ is 0.001%-0.01% in
patients treated with either oral or IV BP therapy. This is only slightly higher than the
approximate 0.001% incidence in the general population (DynaMed Plus, 2017). These values
are hard to access because of no conditions of the studies are listed.
A systematic review of 92 publications evaluating BP MRONJ found an incidence of up
to 12% after 36 months of exposure in cancer patients (Khanet et al., 2009). But in patients with
osteoporosis, the incidence rate was found to be less than one case per 100,000 person-years of
exposure (Khanet et al., 2009).
In one of the most recent meta-analysis of five randomized trials of denosumab versus
bisphosphonates, the studies reviewed used different doses and schedules of administration for
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denosumab and neither of which prospectively evaluated ONJ as an endpoint. The rate of ONJ
was again higher with denosumab, but the difference was not statistically significant (1.7 versus
1.1 percent) (Berenson, Stopeck 2017).
Authors De Paula, et al., (2016) claim the prevalence of MRONJ is very low when
bisphosphonates are used in the doses used to treat osteoporosis. When much higher doses are
used to prevent the skeletal complications of cancer, MRONJ is a substantial concern. However,
in osteoporosis patients, the prevalence is estimated to be less than one in every 100,000 patients
exposed to oral or intravenous BPs who are otherwise healthy.
In another study published in July of 2017, the authors aimed to investigate if switching
to denosumab from a BP is associated with a higher prevalence rate of MRONJ (Loyson et al.,
2017). 110 patients were sequentially treated with BPs followed by denosumab. The median BP
treatment time was 16 months and the median denosumab treatment was 13 months. 240 patients
were in the BPs control group, while 240 patients were included in denosumab control group.
About 6.7% of the patients developed ONJ during BP therapy, and 10% of patients developed
ONJ during denosumab therapy. In the sequential group, 15.5% of patients developed ONJ after
therapy of a BP and then denosumab. The incidence of MRONJ was 1.8%, 6.3%, 4.9%, 5.6%,
and 3.4%, respectively in the first, second, third, fourth, and fifth year of treatment, an MRONJ
incidence similar to that of the denosumab control group (Loyson et al., 2017). The authors
concluded that patients treated for osteoporosis seem to have a slightly higher risk of MRONJ
early after switching from BPs to denosumab compared to patients remaining on BPs. However,
based on the global MRONJ incidence rates, the switch from BPs to denosumab can be
considered as safe as initially starting denosumab therapy (Loyson et al., 2017). This study gave
the some of the best details found regarding the conditions of the study. The drawback of this
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study is the smaller sample size used as well as the congruency of the medications given after
each other, making it difficult to assess which medication, or a combination of both, were
responsible for the MRONJ.
In 2007, a literature review was performed to clarify the relationship between BP use and
development of MRONJ for the treatment of osteoporosis. 11 publications from 1966 to 2006
reporting 26 cases of ONJ in patients being treated with BPs were included. (Pazianas, Miller,
Blumental, Bernal, & Kothawala, 2007). This was one of the lengthiest literature reviews found
that was included information of over nearly 40 years. The incidence rate was not reported by the
authors. However, they did conclude that considering that millions of patients are prescribed
BPs, the relative prevalence of MRONJ in these patients was low (Pazianas et al., 2007). It was
not possible for the authors to draw any further conclusions about the associated between BP use
and MRONJ in these identified studies because of incomplete reporting and the presence of
compounding factors (Pazianas et al., 2007). Without any other statistics reported, it is also
difficult for me to access the quality of this study.
In 2016, several authors conducted a longitudinal study of cases of MRONJ associated
with denosumab and BPs. The incidence of MRONJ in subjects with osteoporosis was estimated
at 0.001-0.01%. MRONJ was more common when BPs were taken intravenously than when
they were taken orally, with between 2% and 9% of patients showing MRONJ with IV BP and
0.00001% patients with oral BP (Bagan et al., 2016).
During my research, I also consulted with Emily Huntley, Physician Assistant of
rheumatology (EH PA-C) at Rapid City Medical Center. She has more than 13 years of clinical
experience and has contact with osteoporosis patients on a daily basis. She is also very familiar
with denosumab and BPs prescribed to treat osteoporosis. In her opinion, she believes the
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rheumatology community is still “skeptical” regarding the reported side effect MRONJ of BPs
and denosumab. She states that the medications are often “blamed” as the reason behind this side
effect, but there are so many other variables and factors that compound the problem, and the
medications are often “over-attributed” to the development MRONJ. She herself has not seen a
case of MRONJ. EH PA-C has done research on the medications and has attended conferences
by the International Endocrinology Society. It is understood that BPs slightly increase a patient’s
chance of MRONJ, but not denosumab. This is somewhat contradictory to what my research has
uncovered. EH PA-C believes that because denosumab is a newer class of medication, it has not
been as studied in long term studies compared to BPs that have been around for years. It is
understood by the professional endocrinology community that without any treatment,
0.6/100,000 people will develop ONJ, while on BP therapy, 1/100,000 patients will (personal
communication, November 29, 2017). So, the risk is very slightly increased by 0.0000094%.
Other stats are also difficult to interpret because many patients have been on BPs for about three
to five years as recommended, prior to switching denosumab therapy. So, if a patient develops
MRONJ, it is hard to determine what medication is specifically to blame.

Table 2: Osteonecrosis of the jaw risk (cases per 10,000 patients)

Note. Adapted from “Medication-related osteonecrosis of the jaw in oncological patients with
skeletal metastases,” by R. Coropciuc, K. Grisar, T. Aerden, M. Schol, J. Schoenaers, and C.
Politis, 2017, British Journal of Oral and Maxillofacial Surgery, 55, p. 787-792. Copyright British
Association of Oral and Maxillofacial Surgeons
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Table 3: Disease frequency of MRONJ among various studies
Indications for
treatment
Malignancy
Guarneri et al
(2010)
Qi et al (2013)
Scagliotti et al
(2012)
Coleman et al
(2001)
Vahtsevanos et al
(2009)
Mauri et al
(2009)
Osteoporosis
Papapoulos et al
(2012)
Grbic et al (2010)

Placebo

Zolendronate

Oral BP

Medications
Denosumab Bevacizumab

0.2% (1076)
0%
(1450)

0%
(1675)

0.019%
(5382)
0%
(3383)
0.020%
(4945)

1.1% (2928)

1.9% (4585)

0.8% (400)

0.7% (411)

Bevacizumab
and
Zolendronate

Study
design

0.9% (233)

Systemic
review
Systemic
review
RCT

0.7% (1665)

RCT

6.7% (1163)

Prospective
cohort study
Systemic
review

0.33% (3987)

0.04%
(4549)

RCT

0.017%
(5864)

Malden and
Lopes (2012)
Lo et al (2010)

Systemic
review
Prospective
cohort study
Crosssectional

0.004%
(90000)
0.1%
(8572)

Note. Sample size in parenthesis
Adapted from “Medication-Related Osteonecrosis of the Jaw” by S. Ruggiero, T. Dodson, J.
Fantasia, R. Goodday, T. Aghallo, B. Mehrota, and F. O’Ryan, 2014, Journal of Oral and
Maxillofacial Surgery, 72, p 1938-1956. Copyright 2014 by American Association of Oral and
Maxillofacial Surgeons.

Table 4: Risk of MRONJ among various studies
Authors, Year
Sugimoto et al., 2014
Bone et al., 2013
Long-term exposure group
(6yr)
Short-term exposure group
(2yr)
Papapoulos et al., 2012
Grbic et al., 2010
Malden and Lopes, 2012
Lo et al., 2010

Placebo

0% (3383)
0.02%
(4945)

Zolendronate

Oral BP

0.02% (5864)
0.004%
(90000)
0.1% (8572)

Denosumab
0.1% (775)
0.2% (2342)

Study design
RCT
RCT
--

0.1% (2207)

--

0.04% (4549)

RCT
Systematic review
Prospective cohort
study
Cross-sectional

Note. Adapted from “The frequency of medication-related osteonecrosis of the jaw and its
associated risk factors,” by T. Dodson, 2014, Oral Maxillofacial Surgical Clinics of North
America, 27 pg 509-516. Copyright 2015 by American Association of Oral and Maxillofacial
Surgeons
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In summary, several studies have reported a slightly higher rate of MRONJ with
denosumab compared to BPs, but the differences have been reported as not statistically
significant (Berenson, Stopeck 2017). However, EH PA-C states that bisphosphonates carry the
higher risk (personal communication, November 29, 2017). This contradiction his is not
surprising as the reported rates vary greatly from study to study, so it is difficult to come to a
definitive conclusion between the two medication classes. Moreover, the risk of MRONJ in
osteoporotic patients receiving antiresorptive therapy continues to be very low regardless of drug
type (BPs, denosumab) or dosing schedule (Ruggiero et al., 2014).
Contributing factors of MRONJ:
Cancer treatment: According to Bagan et al., the incidence of MRONJ is greater in
patients with cancer due to the higher doses of medications. Corresponding to a wide variety of
reported incidence rates of MRONJ caused by BPs or denosumab for the treatment of
osteoporosis, the incidence rates of MRONJ in cancer patients also varies greatly.
The risk of MRONJ in patients with cancer is about 50 times higher than the risk in
patients with cancer exposed to placebo (Dodson, 2014), while another source reports the risk
could be up to 100 times higher (Ruggiero, 2014). According to Dodson (2014), when compared
with osteoporosis patients receiving antiresorptive therapy, the risk of MRONJ in patients with
cancer managed with oral BPs or denosumab is about ten times greater.
Authors Svejda et al., (2016) state the incidence of MRONJ is highest in the oncology
patient population and report a wide range of cases at 1-15% of patients. Among patients with
cancer exposed to intravenous BPs, MRONJ risk ranged from 0% to 6.7% in one study (Dodson,
2014), while another source cited a range of 0.7% to 1.9% (Bagan et al., 2016). Another study
reports the risk of ONJ among patients with cancer exposed to an oral BP to be 0.7% in a sample
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of 704 patients (Dodson, 2014). This study is the only one with a listed sample size, so the
validity of the all of the data is uncertain.
The majority of studies suggest that the best estimate of MRONJ among patients with
cancer exposed to IV BPs is in the low single digit percentages ranging from 1-3%. But again,
most of the study conditions are unknown, which is a significant drawback.
In a review study conducted in 2016, the authors aimed to perform a systematic review of
the relation between treatment with denosumab and the incidence of MRONJ among cancer
patients. A total of 8963 patients with a variety of solid tumors were included. The overall
incidence of MRONJ receiving denosumab was 1.7%. The use of denosumab was associated
with a significantly increased risk of MRONJ in comparison with the placebo control group. The
authors concluded that denosumab combined with other risk factors including cancer treatment,
favor the development of MRONJ (Boquete-Castro, Gomez-Moreno, Calvo, Aquilar, &
Delgado, 2016). The strength of study is significant because of more complete reporting of the
study conditions and large sample size.
Form given: MRONJ was more common when BPs were taken intravenously than when
they were taken orally, with between 2% and 9% of patients showing MRONJ with IV BP and
1/100,000 patient with oral BP (Bagan et al., 2016).
Duration of medication therapy as a risk factor: Regardless of indications for therapy,
the duration of BP or antiresorptive therapy is a significant risk factor for developing MRONJ.
According to Berenson & Stopeck in Up to Date (2017), the incidence is higher with longer
duration of treatment, particularly when the duration of therapy exceeds four years. The onset of
MRONJ may be shortened by the presence of other comorbidities. In a retrospective series of
3994 patients who received IV bisphosphonates, the median duration of pamidronate, a BP, was
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longer in those who developed ONJ compared with those who did not: 1.68 versus 0.59 years in
breast cancer and 1.55 versus 0.3 years in multiple myeloma (Berenson & Stopeck. 2017). The
same findings were noted among patients receiving zoledronic acid, a BP: 2.04 versus 0.73 years
in breast cancer, and 1.85 versus 0.67 years in myeloma. In another study, the cumulative hazard
of developing MRONJ increased according to the duration of IV bisphosphonate therapy: 0
percent at one year to 11 percent at four years. (Berenson & Stopeck, 2017). In patients with
cancer exposed to zoledronate or denosumab, the incidence of developing ONJ was 0.6% or
0.5% after one year of taking the medication, 0.9% or 1.1% after two years, and 1.3% or 1.1%
after three years, respectively (Ruggiero et al., 2014). The same statistics are quoted by Dodson,
2015. The risk for developing MONJ in patients taking denosumab plateaued around two or
three years (Ruggiero et al., 2014). This data is very valid due to complete reporting and direct
comparison of the different treatments. The data is strengthened more by the same statistics
reported by two different sources.
In a study by Saad et al., (2014) the investigators combined three blinded phase trials and
found similar results, including a plateau of incidence rate after two years for patients exposed to
denosumab. In patients with cancer exposed to zoledronate or denosumab (n = 5,723), the
incidence of developing ONJ was 0.5% or 0.8% after one year, 1.0% or 1.8% at two years, and
1.3% or 1.8% at three years, respectively. For patients receiving oral BP therapy to manage
osteoporosis, the prevalence of MONJ increases over time, from nearly 0% at baseline to 0.21%
after at least four years of BP exposure (Ruggiero et al., 2014).
Authors Fleisheret et al., published a review in 2013 of a retrospective cohort study of
patients to identify the onset of ONJ based on the exposure to BP therapy and associated triggers
based on the route of BP administration. The records of 114 patients with a history of ONJ were
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reviewed and divided into cohorts by the route of BP administration, with 76 patients having a
history of IV BP therapy and 38 patients using oral BP treatment. The overall onset of MRONJ
was earlier in the IV BP group, with a median onset of three years. The median onset in the oral
BP group was five years. The authors concluded the median onset of ONJ for patients
undergoing IV BP therapy occurs earlier than the median onset for patients undergoing oral BP
therapy (Fleisher et al., 2013). However, the small sample size is a limiting factor to this study.
Another found that in patients receiving oral BP therapy to manage osteoporosis, the
prevalence of ONJ increases over time from year zero at baseline to 0.2% after four or more
years of BP treatment. After two years of treatment with denosumab, the incidence of MRONJ in
patients was 0.09% and then nearly doubled to 0.2% after six years (Dodson, 2015).
Local factors:
Operative treatment: Patients who undergo dental procedures that invade bone, such as
tooth implantation and tooth extraction, are at increased risk of MRONJ (De Paula, Black, &
Rosen, 2016). Several studies have reported that in patients with MRONJ, tooth extraction is a
common predisposing event, with 52 to 61% of patients reporting tooth extraction as the
precipitating event (Ruggiero et al., 2014). In a case-control study of cancer patients exposed to
zoledronate, tooth extraction was associated with a 16-fold increased risk of MRONJ when
compared with counterparts without MRONJ (OR: 16.4, CI: 95%). The best estimate for the risk
of developing MRONJ after tooth extraction or other dentialveolar procedures in patients
exposed to oral BPs is 0.5% (Ruggiero et al., 2014). This was the one of the only studies found
that reported a confidence interval. But a drawback of this study is that it was done in cancer
patients not in osteoporosis patients, so the patient population varies from the intended
population group, which could highly influence the significance of the results.
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However, in a study by Fleisheret et al., (2013), there was no difference found in rate of
MRONJ occurring spontaneously or after dental extraction. The lack of evidence suggesting
greater onset after dental extraction may provide clinical support for dentialveolar surgery that is
indicated for patients with a history of BP therapy (Fleisher et al., 2013). This study has more
validity to my research as the study observed osteoporosis patient instead of those undergoing
cancer treatment.
Concomitant oral disease: Pre-existing inflammatory dental disease, such as periodontal
disease, is a well-recognized risk factor for developing MRONJ (Ruggiero et al., 2014). Given
that a common treatment of inflammatory dental disease is tooth extraction, pre-existing dental
disease may compound the correlation between tooth extraction and the risk for MRONJ.
According to EH PA-C, it can be a tricky attempting to treat osteoporosis in patients with
oral disease of any kind. In this situation, we as providers have to be able to weigh the benefits of
treating versus the possible risks of treating.
Demographic, systemic, and other medication factors: Age and gender are variably
reported as risk factors for MRONJ. The higher prevalence in the female population is likely a
reflection of the underlying disease for which the agents are being prescribed, i.e., osteoporosis
(Ruggiero et al., 2014). There is very limited data describing the occurrence of MRONJ in the
pediatric population, as denosumab or BPs are very rarely prescribed to pediatric patients.
Corticosteroids are associated with an increased risk of MRONJ as they can further
weaken bones (Ruggiero et al., 2014). Bone loss occurs soon after corticosteroid therapy is
initiated and results from a complex mechanism involving osteoblastic suppression and increased
bone resorption. When high doses of prednisolone greater than 20 mg/day or equivalent are used,
the annual rate of loss of spinal bone density is 5-15% (Romas, 2008). The rate of bone loss is
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most marked in the first six months after starting corticosteroids and can be as high as 27%
(Romas, 2008). In contrast to premenopausal women, people over 50 years of age and
postmenopausal women are more susceptible to osteoporosis, even with lower corticosteroid
doses (Romas, 2008). Any condition that further decreases a person’s bone density increases
their chance of MRONJ, especially in this subset of patients that are already at risk of
osteoporosis.
Tobacco use has been inconsistently reported as a risk factor for MRONJ. In a casecontrol study in 2012, tobacco use approached statistical significance as a risk factor for ONJ in
patients with cancer (OR = 3.0; 95% CI, 0.8-10.4) (Ruggiero et al., 2014). In a more recent casecontrolled studies, the authors were unable to find an association between tobacco use and
MRONJ (Ruggiero et al., 2014).
Genetic factors: There have been several reports describing single nucleotide
polymorphisms (SNPs) that have been associated with developing MRONJ. Most of these SNPs
are located within regions of the gene associated with bone turnover, collagen formation, or
certain metabolic bone diseases. In one study, an ONJ event rate of 57% was reported when
SNPs were present in five candidate genes that were responsible for bone turnover. In a genome
wide study, it was reported that patients with an SNP in a specific gene associated with bone
density and collagen formation, were 5.8 times more likely to develop MRONJ. In a study that
analyzed polymorphisms related to farnesyl diphosphate synthase, an enzyme specifically
inhibited by BPs, a positive correlation was established with the carrier status and MRONJ
(Ruggiero et al., 2014). Collectively, these studies suggest a likely genetic link between MRONJ
and BP therapy.
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According to EH PA-C, if patient has a family history of ONJ, she would potentially not
recommend osteoporosis treatment in the form of BPs or denosumab. In our conversation, we
discussed a hypothetical situation in which if a mother developed MRONJ, would she as a
provider reconsider not initiating osteoporosis treatment in the form of a BP or denosumab for
the daughter. She would potentially not start therapy in this situation, as the patient may have an
increased risk of developing MRONJ. She would however, have an educational conversation
with the daughter as a patient and highly recommended good dental hygiene and regular dental
exams if the patient would choose to start therapy. A family history would not stop EH PA-C
from starting osteoporosis therapy, but she would make sure the patient was well-informed and
educated about the possible increased risk of complications. (personal communication,
November 29, 2017).
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DISCUSSION

The pathophysiology of MRONJ is complex and multifactorial. This paper sought to
answer the questions: is the incidence rate of MRONJ greater in those patients treated with
denosumab or bisphosphonates? And are there any precipitating factors or conditions that
increases incidence rates of MRONJ with treatment of denosumab or bisphosphonates? Upon
review of multiple studies, there are numerous statistical ranges and prevalence rates reported by
numerous associations in different settings and demographics.

Is the incidence rate of MRONJ greater in those patients treated with denosumab or
bisphosphonates?
Among the different studies, the prevalence rate of MRONJ with BP therapy ranged
greatly between 0.0004-9%, and the rate with denosumab varied as well from 0.04-0.2%. One
study reported a slightly higher risk after switching from a BP to a denosumab, from 6.7% to
10% (Loyson et al., 2017). One study found that the rate of MRONJ was also higher with
denosumab, but authors concluded the difference was not statistically significant, as the
difference was 1.7% versus 1.1% (Berenson & Stopeck, 2017). However, these studies used
different doses and schedules of administration, so the varying conditions make it difficult to
compare the results with full confidence. Many studies were unable to draw conclusions based
on the minor differences in statistics, and it is common theme for them to conclude that the
relative prevalence of MRONJ among patients is low.
According to EH PA-C, BPs cause MRONJ while denosumab does not (personal
communication, November 29, 2017). This is somewhat contradictory to some research I have
found, but reiterates the idea that it is very difficult to make a forgone conclusion between the
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two medications. It is reasonable to think that because denosumab is a newer medication, it is not
studied as well as BPs, which have been around for numerous years, and it may be possible for
the known risk of MRONJ with denosumab to increase as the studies increase.
During my research, it was found to be rather difficult to find studies that solely
compared BP with denosumab under the same conditions. Many studies used small and varying
sample sizes, not all studies used control groups, and the lengths of the studies varied or were not
reported. Also, many of the studies compared the rates of MRONJ after treatment of one
medication and then the other. In this situation, it can be near impossible to say with complete
confidence which medication is responsible for the MRONJ, or whether there is a compound
effect of the two medications when used consecutively.
In the general population, it can also be difficult to identify the medication to blame,
because of the common practice of how and when these medications are prescribed. In most
cases, the osteoporosic patient is prescribed BP therapy for about five years until the therapeutic
effect is maximized, and then often the patient is switched to denosumab or another class of
medication to be used chronically. This transitioning to different medications can make it
difficult to pinpoint the specific medication to blame if MRONJ develops. This is consistent with
the information that I received during my interview with EH PA-C as well.
Also, during my search, I found many cases that compared the prevalence rate of
MRONJ in patients with varying comorbidities. This variance makes it not possible to draw
further conclusions about the potential associated between bisphosphonates use and MRONJ in
identified studies because of incomplete reporting and the presence of confounding factors.

PREVALENCE OF MRONJ

27

Are there any precipitating factors or conditions that increases incidence rates of MRONJ
with treatment of denosumab or bisphosphonates?
Denosumab and BPs are often used as treatment for some cancers that can cause bone
damage. The medications are used in higher doses compared to those used for osteoporosis.
Cancer can greatly increase a patient’s risk for MRONJ, but again the prevalence rates reported
vary greatly from 1-15% and up to 50-100 times higher than a patient in the control group. This
is logical, as a patient would have a greater chance of jaw bone necrosis if there is previously
compromised bone strength due to cancer.
There are many different comorbidities that greatly increase the patient’s chance of
MRONJ. One of the greatest risk factors is dental procedures. One study found that in patients
with MRONJ, 52-61% reported a history of tooth extraction (Ruggiero et al., 2014). However, a
different study found no difference in MRONJ onset after tooth extraction (Fleisheret et al.,
2013).
Age and gender are variably reported as risk factors. A higher prevalence rate is
consistent with the population of patients treated for osteoporosis, which is normally aging
females. Corticosteroid use is also associated with increasing risk, as they can further weaken
bones (Ruggiero et al., 2014). Studies including tobacco use shows inconclusive MRONJ
association.
There could also possibly be a genetic link to developing MRONJ. One study reported an
MRONJ rate of 57% with SNPs present on genes responsible for bone turnover (Ruggiero et al.,
2014). Another study found that patients were 5.8 times more likely to develop MRONJ with an
SNP in a specific gene that is associated with bone density and collagen formation (Ruggiero et
al., 2014).
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Although there are several risk factors to developing MRONJ, EH PA-C stated that not
all risks are treated equally, and not all risk factors should prevent us as providers from halting
therapy (personal communication, November 29, 2017). We as providers need to weigh the
benefits versus risks for all the risk factor and base our decisions to treat with each individual
patient in mind.
In summary, my research is mostly inconclusive. While a few source states a higher
incidence rate of denosumab, most have inconclusive results or are unable to draw a conclusion.
The wide ranges of reported prevalence rates of MRONJ in different studies under different
conditions makes it extremely difficult to determine what class of medications, BPs or
denosumab, causes the higher prevalence rate of MRONJ. I am unable to draw my own
conclusion about what medication class causes the greatest risk of MRONJ; however, I was able
to uncover numerous comorbidities and risk factors that would increase the chance of MRONJ.
Although I was not successful in answering one of my research questions, I believe my research
was successful as it allows for the acquisition of knowledge and application to future practice. I
agree with several statements my research uncovered that the risk of MRONJ in osteoporotic
patients receiving antiresorptive therapy continues to be very low regardless of drug type (BPs,
denosumab) or dosing schedule (Ruggiero et al., 2014).
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APPLICABILITY TO CLINICAL PRACTICE
My research was to determine which medication class has the highest prevalence rate of
MRONJ and to uncover possible the risk factors. So how does this research apply to clinical
practice? The baby boomer generation in the United States continues to age, and the population
of Americans aged 65 years or older during the next 25 years is expected to double to about 72
million (CDC, 2013). In fact, by 2030, older adults are expected to account for roughly 20% of
the U.S. population (CDC, 2013). During my clinical experiences, I have cared for many elderly
patients. As potential future family practice providers, a large proportion of our patients will lie
in this age range, so it is imperative to be aware of common conditions that could affect this
population. Because of the USPSTF recommendation of bone density scans, many patients will
have the diagnosis of osteopenia and/or osteoporosis. Both conditions can be debilitating and
cause significant physical impairment if left untreated, with hip fracture being one of major
significance.
Hip fracture in older adults is a leading public health concern. Hip fractures are
associated with significant increased risk of mortality, loss of independence, and financial
burden. In one study, the reported one-year mortality after sustaining a hip fracture was
estimated to be 14% to 58% (Schnellet et al., 2010). A recent meta-analysis revealed that women
sustaining a hip fracture had a five-fold increase and men almost an eight-fold increase in
relative likelihood of death within the first three months following the injury as compared with
age and sex-matched controls (Schnellet et al., 2010). Loss of function and independence among
survivors is profound, with 40% of patients unable to walk independently and 60% requiring
assistance one-year post-fracture. (International Osteoporosis Foundation, 2017). Because of
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these losses, 33% of patients are completely dependent or in a skilled nursing facility in the year
following a hip fracture (International Osteoporosis Foundation, 2017).
Because osteoporosis is becoming more and more prevalent as the baby boomers age, it
is imperative to make every attempt to prevent hip and other fractures. This can be accomplished
by following the recommended guidelines for bone density scans and by treating osteopenia and
osteoporosis appropriately.
There are many different treatment options for osteoporosis, among them BPs and
denosumab. Both treatments have their associated side effects, and it’s crucial that we are aware
of the different side effects for each. However, because there are many different classes of
medications, there is not a one-size-fits-all solution for osteoporosis treatment. In any situation,
we as providers have to be able to weigh the benefits of treating versus the possible risks of
treating. We will need to take each patient’s preference and personal medical history in to
account to make a joint decision about what treatment is right for them.
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